- Home
- CGTX vs CALC Comparison
CGTX vs CALC Comparison
Compare CGTX & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- CALC
- Stock Information
- Founded
- CGTX 2007
- CALC 2011
- Country
- CGTX United States
- CALC United States
- Employees
- CGTX N/A
- CALC N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CGTX Health Care
- CALC Health Care
- Exchange
- CGTX Nasdaq
- CALC Nasdaq
- Market Cap
- CGTX 23.1M
- CALC 20.9M
- IPO Year
- CGTX 2021
- CALC N/A
- Fundamental
- Price
- CGTX $0.28
- CALC $2.07
- Analyst Decision
- CGTX Strong Buy
- CALC Strong Buy
- Analyst Count
- CGTX 5
- CALC 3
- Target Price
- CGTX $6.13
- CALC $16.33
- AVG Volume (30 Days)
- CGTX 692.0K
- CALC 28.2K
- Earning Date
- CGTX 05-07-2025
- CALC 05-20-2025
- Dividend Yield
- CGTX N/A
- CALC N/A
- EPS Growth
- CGTX N/A
- CALC N/A
- EPS
- CGTX N/A
- CALC N/A
- Revenue
- CGTX N/A
- CALC N/A
- Revenue This Year
- CGTX N/A
- CALC N/A
- Revenue Next Year
- CGTX N/A
- CALC N/A
- P/E Ratio
- CGTX N/A
- CALC N/A
- Revenue Growth
- CGTX N/A
- CALC N/A
- 52 Week Low
- CGTX $0.31
- CALC $1.43
- 52 Week High
- CGTX $2.95
- CALC $6.02
- Technical
- Relative Strength Index (RSI)
- CGTX 31.37
- CALC 69.21
- Support Level
- CGTX $0.40
- CALC $1.52
- Resistance Level
- CGTX $0.47
- CALC $2.15
- Average True Range (ATR)
- CGTX 0.03
- CALC 0.13
- MACD
- CGTX -0.01
- CALC 0.08
- Stochastic Oscillator
- CGTX 2.76
- CALC 88.89
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.